Re­port of shoot­ing in ho­tel de­layed

Pittsburgh Post-Gazette - - National -

Com­piled from news ser­vices

Man­dalay Bay ho­tel of­fi­cials didn’t no­tify po­lice about a shoot­ing in a hall­way in­side the Las Ve­gas high-rise un­til af­ter Stephen Pad­dock opened fire on the crowd at a coun­try mu­sic fes­ti­val out­side, a fed­eral of­fi­cial told The As­so­ci­ated Press on Thurs­day.

The dis­clo­sure means there may have been a de­lay of some six min­utes in sum­mon­ing po­lice to the scene of what be­came the dead­li­est mass shoot­ing in mod­ern U.S. his­tory. The of­fi­cial was briefed by law en­force­ment and spoke on con­di­tion of anonymity.

Truck­ing firm closed

IOWA CITY, Iowa — Fed­eral safety reg­u­la­tors have shut down a trou­bled Iowa truck­ing com­pany that owned the semi­trailer in­volved in a hu­man traf­fick­ing case in which 10 im­mi­grants died in Texas.

Pyle Trans­porta­tion was placed un­der an “out-of-ser­vice or­der” Mon­day by the Fed­eral Mo­tor Car­rier Safety Ad­min­is­tra­tion af­ter a re­view found the com­pany’s safety rat­ing was so un­sat­is­fac­tory that it was un­fit to re­main in busi­ness, an agency spokesman said.

Dozens of im­mi­grants were found in­side a Pyle branded semi­trailer in July in San An­to­nio. Eight were dead. Two oth­ers died later.

Equifax web­site down

WASH­ING­TON— Equifax Inc. took part of its web­site off­line Thurs­day af­ter code on the site redi­rected users to a URL urg­ing them to down­load mal­ware.

Also Thurs­day, a Re­pub­li­can con­gress­man in­tro­duced a bill that would stop credit re­port­ing com­pa­nies such as Equifax from us­ing So­cial Se­cu­rity num­bers to ver­ify Amer­i­cans’ iden­ti­ties.

The moves come a month af­ter Equifax re­vealed that a data breach ex­posed the So­cial Se­cu­rity num­bers and birth­dates of as many as 145.5 mil­lion Amer­i­cans.

Gene ther­apy en­dorsed

SIL­VER SPRING, Md. — A po­ten­tially ground­break­ing treat­ment for a rare form of blind­ness moved closer to U.S. ap­proval Thurs­day, as fed­eral health ad­vis­ers en­dorsed the ex­per­i­men­tal gene ther­apy to treat an in­her­ited con­di­tion that grad­u­ally de­stroys eye­sight.

The panel ex­perts to the Food and Drug Ad­min­is­tra­tion voted unan­i­mously in fa­vor of Spark Ther­a­peu­tics’ in­jectable ther­apy, which aims to im­prove vi­sion by re­plac­ing a de­fec­tive gene needed to process light. The FDA has un­til mid-Jan­uary to make its de­ci­sion.

If ap­proved, Lux­turna would be the first gene ther­apy in the U.S. for an in­her­ited dis­ease and the first in which a cor­rec­tive gene is given di­rectly to pa­tients.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.